GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Short-Term Debt

CARISMA Therapeutics (FRA:W2J) Short-Term Debt : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Short-Term Debt?

CARISMA Therapeutics's Short-Term Debt for the quarter that ended in Sep. 2024 was €0.00 Mil.


CARISMA Therapeutics Short-Term Debt Historical Data

The historical data trend for CARISMA Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Short-Term Debt Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Debt
- - - -

CARISMA Therapeutics Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CARISMA Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


CARISMA Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


CARISMA Therapeutics Business Description

Traded in Other Exchanges
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines